NCT03524833View on ClinicalTrials.gov

Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

January 8, 2019

Study Completion Date

February 8, 2019

Conditions
Helicobacter Pylori Infection
Interventions
DRUG

Metronidazole

Twenty patients receive intraluminal Metronidazole eradication of H. pylori.

DRUG

Lansoprazole, Amoxicillin, Metronidazole

Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.

Trial Locations (1)

10449

Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan, Taipei

All Listed Sponsors
lead

Mackay Memorial Hospital

OTHER

NCT03524833 - Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection | Biotech Hunter | Biotech Hunter